Visiopharm’s Precision Pathology APPs ​​​to be ​Integrated with PathAI’s AISight Image Management System 

Hørsholm, Denmark — Visiopharm, a world leader in AI-driven precision pathology, is thrilled to become a preferred partner to PathAI with the integration of its precision pathology APPs into the AISight^Ⓡ1 Image Management System (IMS). This partnership underscores Visiopharm’s commitment to transforming diagnostic and translational pathology workflows by enabling PathAI’s AISight IMS users to analyze images with unparalleled accuracy and speed.

Visiopharm offers a comprehensive suite of diagnostic APPs, including a breast panel (HER2, ER, PR, metastasis detection, and Ki-67), and a non-small cell lung cancer (PD-L1) APP. These APPs are IVDR-cleared for use in the EU and UK and designated for research use in other regions. These tools will empower pathology laboratories with high-performance algorithms designed to streamline workflows and enhance diagnostic precision.

PathAI’s AISight IMS is designed to enhance interoperability and efficiency in digital pathology. Laboratories using AISight can seamlessly access a diverse portfolio of digital pathology algorithms from leading global AI providers, including Visiopharm. Pathologists will benefit from rich visual support, including AI-generated overlays and embedded quantitative results, driving more informed decision-making and differentiated workflows.

“We are excited to collaborate with Visiopharm and integrate their leading AI image analysis technologies into our AISight platform,” said Andy Beck, CEO of PathAI. “This partnership reinforces our mission to provide pathologists with comprehensive, state-of-the-art tools that enhance precision and increase workflow efficiency in the pathology laboratory. By incorporating Visiopharm’s innovative solutions, we are broadening access to top-tier AI capabilities, ultimately driving better patient outcomes and setting a new standard in digital pathology.”

Michael Grunkin, CEO of Visiopharm, expressed his enthusiasm about the partnership: “We are delighted to collaborate with PathAI to bring our portfolio of fully automated AI-driven diagnostic and translational solutions for breast and lung cancer to a broader audience. Our commitment is to expand access to precision pathology on leading platforms. Becoming ​​​​a preferred partner for PathAI’s AISight Image Management System is an important step towards this goal. With our platform-agnostic technology designed for seamless integration, we look forward to working closely with the PathAI team to accelerate the adoption of digital pathology worldwide, ultimately enhancing lab efficiency and improving the quality of patient care.”

​​Pathology laboratories worldwide are invited to experience the power of Visiopharm’s precision pathology APPs on PathAI’s AISight IMS. To schedule a demonstration of the APPs, please contact us at https://visiopharm.com/. ​​

​​​​​ 

​​​¹AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK​​ 

About Visiopharm 

Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

For more information visit visiopharm.com. 

About PathAI
PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe.